查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190466

化妆品Peptide合成市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Cosmetic Peptide Synthesis Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，化妆品Peptide合成市场预计将以 5.5% 的复合年增长率註册。

大流行对化妆品行业，包括化妆品Peptide合成行业产生了整体的负面影响。 例如，2021 年 10 月发表的一项研究报告《疫情期间的美丽。在使用方面，眼部、唇部和皮肤化妆品的使用量有望恢復到 COVID 之前的水平。 儘管预计 2020 年会出现大幅下降，但美国化妆品行业预计使用量将恢復到 COVID 前的结果，并带有 COVID 后的意向。 预计护肤品类别在 COVID 中期几乎不会下降，而在 COVID 后会有所增长。 强烈建议将护肤产品作为新产品系列推出，因为它们在改变行业的大流行病中是可持续的。 同样，在 2020 年 10 月发表在国际饮食失调杂誌上的另一篇论文“了解 COVID-19 期间美容行业停工的影响”中，斯威本心理健康中心 (CMH) 的研究人员领导的一项研究发现，大多数人们报告说，自 COVID-19 开始以来，他们花在外表上的时间减少了，但那些高度畸形的人继续对自己的外表感到难为情。说

眼睛和皮肤疾病的增加是市场增长的重要因素之一。 根据加拿大青光眼研究协会的数据，到 2021 年，加拿大将有大约 400,000 人患有青光眼。 根据同一份文件，随着人口老龄化和婴儿潮一代的老龄化，未来患有青光眼的人数将会增加。 这将增加对美容□的需求。 因此，增加未来的市场增长。 同样，根据澳大利亚健康与福利研究所的数据，2021 年约有 166,878 例皮肤黑色素瘤新病例被确诊。 Soukur 说有 9,869 名男性和 7,009 名女性被确诊。 2019 年，年龄标准化死亡率为每 10 万人 4.5 人（男性 6.6 人，女性 2.8 人）。 2021 年的年龄标准化死亡率估计为每 100,000 人 4.0 人（男性 5.6 人，女性 2.6 人）。 皮肤黑色素瘤的死亡率预计会随着年龄的增长而增加。 因此，可以通过使用美容□来避免皮肤癌的增加。 因此，预计癌症患病率的增加将增加未来的市场增长。

采用化妆品□的主要挑战之一是人们仍然认为化妆品不具有药用价值。 例如，2021 年 12 月在国家医学图书馆发表的一篇论文是权威的，证明患有糖尿病性视网膜病变的人与进行连续眼科筛查之间存在直接关联。他说没有研究。 早期检测是能够为患有后节段疾病的患者提供治疗的因素之一，但是，由于患者开始治疗缓慢，缺乏意识阻碍了市场增长。 然而，低意识可能会延迟患者开始治疗，阻碍市场增长。

化妆品Peptide合成市场趋势

眼部护理领域预计在预测期内将占据很大的市场份额

眼睛疲劳加剧是市场增长的主要驱动力之一。 例如，根据世界卫生组织 2021 年 10 月的报告，全球约有 22 亿人患有近视或远视，其中约有 10 亿的视力损害病例是可以预防或预防的。全球视力损害病例的高负担和治疗潜力是治疗眼部相关疾病的药物需求非常高的原因，这推动了研究市场的增长。

青光眼流行病学”，根据 2020 年 11 月发表的一项研究报告。 根据过去、现在和未来的预测，青光眼是由血管、遗传、解剖学和免疫学因素共同引起的，可导致不可逆转的失明，使其成为仅次于白内障的第二大失明原因。据说是一个严重的健康问题，因为它是第二高的 根据同一项研究，全球估计有 5750 万人患有原发性开角型青光眼 (POAG)，预计到 2040 年这一数字将达到 1.118 亿，这是一个非常高的数字。由于患者数量大幅增加，全球对有效疗法的需求也有望增加。 对治疗剂不断增长的需求将增加美容□的消费，促进未来的市场增长。

此外，老化是视力损害的一个新因素。 根据联合国公布的《2020年世界人口老龄化亮点》，2020年世界老年人口（65岁及以上）将达到7.27亿，预计到2050年底将达到15亿。 全球老年人口的增加将对研究领域的增长产生重大影响，因为一些眼病与年龄有关，并且已证实其患病率在老龄化社会中最高。我猜。 随着年龄的增长，我们需要摄入更多的美容□。 因此，由于上述因素，未来市场可能会增长。

北美有望在预测期内主导市场

预计在整个预测期内，北美将主导整个化妆品□合成市场。 这一优势归因于眼部和皮肤病患病率的增加、公共和私人组织的研发和投资增加以及意识计划。

美国製药业长期以来一直是新药发现的领导者，美国研究与製药商协会 (PhRMA) 的成员继续走在前列。 根据美国研究和製药製造商协会 2020 年版的数据，美国製药公司在 2019 年的研发支出约为 830 亿美元，高于 2010 年的 507 亿美元。 根据美国疾病控制与预防中心（CDC）公布的数据，2020年约有410万美国人患有糖尿病视网膜病变，近90万美国人面临视力受损的视网膜病变威胁。据说 糖尿病性视网膜病变是具有代表性的眼科疾病之一。 患病率的上升将增加大量人口的治疗需求，并推动该国的市场增长。

该国皮肤病的增加是市场增长的关键因素。 例如，加拿大皮肤病协会2020年发布的一份报告称，约有8000人患有黑色素瘤皮肤癌，其中男性约4400人，女性约3600人。 黑色素瘤目前是加拿大第七大最常见的癌症，也是少数在加拿大人中患病率上升的癌症之一。 根据 2019 年 10 月发表的“胶原蛋白补充剂改善皮肤水合作用、弹性、粗糙度和密度”研究，“胶原蛋白补充剂改善皮肤水合作用、弹性、粗糙度和密度：随机安慰剂的结果——根据对照、盲法研究、安慰剂对照临床试验已经证实，老化的皮肤可以用可以恢復皮肤水分含量、弹性和密度的营养素来对抗。 因此，研究表明，使用□可以减缓通常伴随衰老而来的胶原蛋白生成的下降。

对皮肤病学的认识也是推动市场增长的因素之一。 例如，2022 年 5 月将举办儿科皮肤病学管理挑战国际会议 (ICCDMP)（加拿大蒙特利尔）和法医病理学和皮肤病学国际会议 (ICFPD)（加拿大温哥华）。 同样，许多会议在 6 月、7 月、8 月和 9 月举行，预计 2023 年将举行更多会议。 在这些会议上，讨论了与皮肤病相关的问题和治疗。 由于美容□在皮肤治疗中发挥着重要作用，会议数量的增加有望提高人们对皮肤疾病的认识，并增加针对此类疾病的美容□相关产品的消费量。 因此，市场规模将会扩大。

因此，上述因素预计将在预测期内推动该地区的市场增长，并有助于其在全球化妆品□合成市场中占据显着的市场份额。

化妆品Peptide合成市场竞争分析

化妆品Peptide合成市场与几家主要参与者竞争适中。 一些公司通过收购、合併和研究合作等各种战略扩大其市场地位，而另一些公司则推出新产品以保持其市场份额。 2019年5月，CEM公司推出全球首台大型全自动微波Peptide合成仪“Liberty PRO”。 该系统能够利用最大 15 升的反应容器每批次合成 1 千克粗□，具有无与伦比的纯度、速度和废物减少，推动市场收入份额。 目前在收入方面主导该行业的主要参与者是 AAPPTec、CSBio Company Inc.、Biotage AB、Bachem Holding AG 和部分 CEM Corporation。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 眼睛和皮肤病的增加
    • 激活研发
  • 市场製约因素
    • 化妆品Peptide审批的严格规定
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按技术
    • 固相
    • 液相
    • 杂交和重组
  • 通过使用
    • 抗衰老
    • 眼部护理
    • 抗色素沉着
    • 头髮生长
  • 最终用户
    • 製药和生物技术公司
    • 合同开发和製造组织 (CDMO)
    • 学术和研究机构
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • AAPPTec
    • Activotec
    • Active Peptide
    • Bachem Holding AG
    • Bio Basic Inc
    • Bio Synthesis
    • CEM Corporation
    • Creative Peptides
    • CSBio Company Inc.
    • GenScript
    • Merck KGaA
    • RS Synthesis, LLC
    • vivitide

第7章 市场机会与今后动向

简介目录
Product Code: 90442

The cosmetic peptide synthesis market is expected to register a CAGR of 5.5 % over the forecast period of 2022-2027.

The pandemic has an overall negative impact on the cosmetic industry including the cosmetic peptide synthesis industry. For instance, the research study published in October 2021, titled "Beauty During a Pandemic: The Impact of COVID-19 on the Cosmetic Industry" stated significant differences in cosmetic usage; however, post-COVID predicted usage indicates that cosmetic usage will revert back to pre-COVID levels for eye, lip, and skin cosmetics. Despite that the US Cosmetic Industry expected a significant decline in 2020, usage is predicted to return to pre-COVID results for post intentions. The skincare category had little decline mid-COVID and is expected to increase post-COVID. Implementing skincare products as a new product line is highly recommended due to its sustainability through an industry-changing pandemic. Similarly, another article published in October 2020 in the International Journal of Eating Disorders titled "Understanding impacts of the beauty industry shutdown during COVID-19" stated that the study led by researchers from Swinburne's Centre for Mental Health (CMH) has found that while most people reported spending less time investing in their appearance since COVID-19 began, individuals with high dysmorphic concern continued to feel self-conscious about their appearance.

Factors such as increasing disorders of eyes and skin are one of the key factors for the growth of the market. According to Glaucoma Research Society of Canada around 400,000 people were suffering from Glaucoma in Canada for the year 2021. According to the same source with increasingly ageing population and an aging baby boom generation, many more people will have glaucoma in the future. This would increase the demand for the cosmpetic peptides. Thus, increasing the growth of the market in the upcoming future. Similarly, according to the Australian Institute of Health and Welfare in 2021, around 16,6878 new cases of melanoma of the skin were diagnosed. The same soucre stated that 9,869 males and 7,009 females were diagnosed. In 2019, the age-standardised mortality rate was 4.5 deaths per 100,000 persons (6.6 for males and 2.8 for females). In 2021, it is estimated that the age-standardised mortality rate will be 4.0 deaths per 100,000 persons (5.6 for males and 2.6 for females). The mortality rate for melanoma of the skin is expected to increase with age. Hence, increasing skin cancer could be avioded by the usage of cosmetic peptides. Thus, increasing prevalence of cancer would increase the market growth in upcoming future.

Awareness is one of the key issue for adopting the cosmetic peptides are people still believes that cosmtics does not provide medicinal benifits. For instance, in December 2021 a paper published in National Library of Medicine stated that there is no conclusive study that proves direct correlation between people suffering from diabetic retinopathy and going for continuous eye screening. Early detection is one of the factors that could provide the treatment for the patients suffering from posterior segment eye disorders however lack of awareness would hinder the growth of the market as patient would start treatment at the later stages. Hence, due to above mentioned factors the market is likely to grow in the future.

Cosmetic Peptide Synthesis Market Trends

Eye Care Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Increasing eye burden is one of the key factors for the growth of the market. For instance, according to the October 2021 report of the World Health Organization, about 2.2 billion people around the world have near or distance vision impairment, of which approximately 1 billion cases of vision impairment can be prevented or could have been prevented which shows the high burden of the cases of vision impairment around the world and possibility of treatment which is why there is a very high demand of the therapeutics for the diseases associated with eyes that are driving the growth of the studied market.

According to the research study published in November 2020, titled "Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future", glaucoma occurs due to the combination of vascular, genetic, anatomical, and immune factors and is a significant health concern as it can cause irreversible blindness and is the second leading cause of blindness after cataracts. As per the same study, it is estimated that approximately 57.5 million people around the world are affected by the primary open-angle glaucoma (POAG) which is expected to reach 111.8 million by 2040, which is a very significant increase and thus, the demand for effective therapeutics is also expected to increase around the world. Increasing therapuetics demands would increase the consumption of cosmetic peptides which will increase the market growth in the future.

Ageing is also an additional factor for eye sight related disorder. According to the World Population Ageing Highlight of 2020 published by the United Nations, the global geriatric population (people of age 65 years or more) was 727 million in 2020 and is expected to reach 1.5 billion by the end of the 2050. Thus, growing global geriatric population will have a significant impact on the growth of the studied segment as it is observed that some of the eye disorders are age related and their prevalence was found highest in the ageing population. Increasing ageing populaiton would require to consume higher amount of cosmetic peptides. Hence, due to above mentioned factors the market is likely to grow in the future.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall cosmetic peptide synthesis market throughout the forecast period. The dominance is due to the growing prevalence of eye and skin disorders, and increasing R&D and investment via public and private organizations coupled with awareness programs.

The pharmaceutical sector in United States has long been a leader in the creation of new medications, and member businesses of the Pharmaceutical Research and Manufacturers of America (PhRMA) continue to remain at the forefront. According to the Pharmaceutical Research and Manufacturers of America 2020, pharmaceutical companies in United States spent roughly USD 83 billion on R&D in 2019, up from USD 50.7 billion in 2010. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2020 around 4.1 million Americans are affected with diabetic retinopathy, and nearly 900,000 Americans are threatened with vision-damaging retinopathy. Diabetic retinopathy is one of the leading disorders of eye disorders. Increasing prevalence will increase the demand for treatment in huge population which will boost the growth of the market in the country.

Increasing number of skin disorders in the country is a key factor for the growth of the market. For instance, in 2020 a report published by Canadian Dermatology Association stated that around 8,000 people are suffering from Melanoma skin cancer our of which around 4,400 were men and 3,600 were women. Melanoma is now the 7th most common cancer in Canada and one of the few cancers with incidence rates on the rise among Canadians. According to the research study published in October 2019, titled "A Collagen Supplement Improves Skin Hydration, Elasticity, Roughness, and Density: Results of a Randomized, Placebo-Controlled, Blind Study" stated that placebo-controlled clinical trial confirmed that skin aging could be addressed using nutrients that are able to restore skin hydration, elasticity, and density. Hence, the research suggests that the use of peptides can slow down the decline in collagen production that usually occurs with ageing.

Awareness of dermatology is another factor in the growth of the market. For instance, in May 2022 there are two conferences namely, the "International Conference on Challenges in Dermatology Management in Pediatrics (ICCDMP)" (Montreal, Canada) and the "International Conference on Forensic Pathology and Dermatology (ICFPD)" (Vancouver, Canada) are expected to held. Similarly, there are many conferences in June, July, August, and September followed by conferences in 2023 are expected to held. These conferences would discuss the issues and treatment reated to dermatological disorders. As cosmetics peptides play a crucial role in the treatment of skins, as the numebr of conferences increases the awarenss for skin disoder will increase along with the consumption of the cosmetic peptide related products for those disorders. Hence, this will increase the market growth.

Hence, the above mentioned factors are likely to fuel the market growth in this region across the forecast period, contributing to its outstanding market share in the global cosmetic peptide synthesis market​

Cosmetic Peptide Synthesis Market Competitive Analysis

The cosmetic peptide synthesis market is moderately competitive, with several major players. Some companies are expanding their market position by adopting various strategies, such as acquisitions, mergers, and research collaborations, while others are introducing new products to maintain their market share. In May 2019, CEM Corporation launched Liberty PRO, the world's first-ever large-scale automated microwave peptide synthesizer. The system can synthesize 1 kg of crude peptide per batch utilizing a reaction vessel, with sizes up to 15 liters with unmatched purity, speed, and waste reduction fueling the market revenue share. A few of the major players currently dominating the industry in terms of revenue are AAPPTec, CSBio Company Inc., Biotage AB, Bachem Holding AG, and CEM Corporation.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Eye and Skin Disorders
    • 4.2.2 Increasing Research and Development Activities
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulation for Approval of Cosmetic Peptide
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Solid-Phase
    • 5.1.2 Liquid-Phase
    • 5.1.3 Hybrid and Recombinant
  • 5.2 By Application
    • 5.2.1 Anti Ageing
    • 5.2.2 Eye Care
    • 5.2.3 Anti Pigmentation
    • 5.2.4 Hair Growth
  • 5.3 By End User
    • 5.3.1 Pharmaceutical and Biotechnology Companies
    • 5.3.2 Contract Development and Manufacturing Organization (CDMO)
    • 5.3.3 Academic and Research Institutes
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AAPPTec
    • 6.1.2 Activotec
    • 6.1.3 Active Peptide
    • 6.1.4 Bachem Holding AG
    • 6.1.5 Bio Basic Inc
    • 6.1.6 Bio Synthesis
    • 6.1.7 CEM Corporation
    • 6.1.8 Creative Peptides
    • 6.1.9 CSBio Company Inc.
    • 6.1.10 GenScript
    • 6.1.11 Merck KGaA
    • 6.1.12 RS Synthesis, LLC
    • 6.1.13 vivitide

7 MARKET OPPORTUNITIES AND FUTURE TRENDS